Beta
Back to PFE.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
cash-and-debt-chart

PFE Cash & Debt

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

In Q4'25, Pfizer's cash and short-term investments stood at $13.6B USD, reflecting a modest decline from $14.98B USD in Q3'25, while total debt increased slightly to $64.8B USD from $61.71B USD in the prior quarter. This positions the company's net cash position at a deficit of approximately $51.2B USD, indicating ongoing liquidity pressures amid debt management efforts. Over the period from Q1'23 to Q4'25, cash levels exhibited significant volatility, peaking at $44.79B USD in Q2'23 before dropping sharply to $7.1B USD in Q2'24 and recovering to $20.48B USD in Q4'24, ultimately stabilizing around $13-17B USD in 2025 with a downward trend. In contrast, debt rose from $35.89B USD in Q1'23 to a high of $71.89B USD in Q4'23, then gradually declined to $61.71B USD by Q2'25 before a slight uptick, highlighting a net debt burden that has widened overall and underscores the need for strategic cash flow improvements to mitigate financial leverage.